β¨ Medicines Notices
8 FEBRUARY NEW ZEALAND GAZETTE
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Methadone hydrochloride 0.2% w/v (10 mg/5 mL) | Linctus | Stevens Chem Industries (NZ) Limited, Pakuranga, Auckland | Methaforte Linctus |
| Nedocromil sodium 2 mg per actuation | Spray, metered dose for inhalation | Fisons Plc., Holmes Chapel, Crewe, Cheshire, England and Fisons Plc., Loughborough, Leicestershire, England | Tilade |
| Diclofenac sodium 75 mg/3 mL | Injection (ampoule) | Ciba-Geigy AG, Stein, Switzerland | Voltaren |
Dated this 31st day of January 1996.
HUGH BABER, Assistant General Manager, Health Regulation & Protection, pursuant to delegation given by the Minister of Health on 18 January 1996.
g0786
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Benzylpenicillin sodium 300 mg, 600 mg, 1.2 g, 3 g | Powder for injection, vials | CSL Limited, Parkville, Victoria, Australia | Benpen |
| Prednisone 2.5 mg, 5 mg, 10 mg, 20 mg, 50 mg | Tablets | Upjohn Company Inc., Kalamazoo, Michigan, United States of America | Deltasone |
| Pseudoephedrine hydrochloride 7.5 mg/0.8 mL in 15 mL | Syrup | Sigma Pharmaceuticals Pty Limited, Clayton, Victoria, Australia | Orthoxicol for Infants Runny Nose Syrup |
| Pholcodine 5 mg/5 mL in 2 L Note: Not to be marketed as substitutable for any other pholcodine product as if the two (2) products were bioequivalent. | Linctus | Douglas Pharmaceuticals Limited, Mount Wellington, Auckland | Pholcodine Linctus |
| Pholcodine 10 mg/5 mL in 2 L Note: Not to be marketed as substitutable for any other pholcodine product as if the two (2) products were bioequivalent. | Linctus | Douglas Pharmaceuticals Limited, Mount Wellington, Auckland | Pholcodine Linctus (Strong) |
| Calcium carbonate 680 mg, magnesium carbonate heavy 80 mg | Tablet | Laboratoires Roche Nicholas SA., Gaillard, France | Rennie |
| Dextromethorphan hydrobromide 15 mg, pseudoephedrine hydrochloride 30 mg in 10 mL in 100 mL, 200 mL | Syrup | Wyeth Australia Pty Limited, Smithfield, New South Wales, Australia | Robitussin DM-P Elixir |
| Guaiphenesin 20 mg, pseudoephedrine hydrochloride 6 mg per mL in 100 mL, 200 mL | Liquid | Wyeth Australia Pty Limited, Smithfield, New South Wales, Australia | Robitussin PS |
| Polyvinyl alcohol 1.4%, povidone 0.6% in 15 mL | Eye drops | Ciba Vision β Sterile Manufacturing, Mississauga, Ontario, Canada | Tear Drops |
| Ascorbic acid 1000 mg, calcium carbonate 300 mg, calcium glycerophosphate anhydrous 327.5 mg, calcium pantothenate 25 mg, cyanocobalamin 10 mcg, nicotinamide 50 mg, pyridoxine hydrochloride 10 mg, riboflavin 15 mg, thiamine hydrochloride 15 mg | Tablet | Adcock Ingram Self Medication, Mobena, Republic of South Africa | Vitaplus B Plus |
Dated this 5th day of February 1996.
HUGH BABER, Assistant General Manager, Health Regulation and Protection, pursuant to delegation given by the Minister of Health on 18 January 1996.
g0874
Next Page →
PDF embedding disabled (Crown copyright)
View this page online at:
VUW Te Waharoa —
NZ Gazette 1996, No 11
NZLII —
NZ Gazette 1996, No 11
β¨ LLM interpretation of page content
π₯
Consent to the Distribution of Changed Medicines
(continued from previous page)
π₯ Health & Social Welfare31 January 1996
Medicines Act, Changed Medicines, Health Regulation
- Hugh Baber, Assistant General Manager, Health Regulation & Protection
π₯ Consent to the Distribution of New Medicines
π₯ Health & Social Welfare5 February 1996
Medicines Act, New Medicines, Health Regulation
- Hugh Baber, Assistant General Manager, Health Regulation and Protection